A living evidence approach treats evidence as shared infrastructure rather than as a series of isolated projects.

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

AI can accelerate drug discovery, clinical development, and patient access, but regulatory hurdles remain. Anders Romare, ...

Quick Read Eli Lilly (LLY) and Nvidia (NVDA) will invest up to $1B over five years in an AI drug discovery lab. AI could reduce pharma R&D costs by 30% to 40% and shorten timelines by one to four ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

Marketers see trust building as a better application of AI than just cost-cutting. Marketers should be co-creating with patients to ensure the content they create is authentic and accurate. Guardrails ...

Large-cap companies are seeing steady AI-related productivity gains since the release of OpenAI's ChatGPT model in 2022 in terms of their real revenue per worker, while small-cap names are seeing a ...

Microsoft CEO Satya Nadella says AI must improve lives and drive growth, warning that unequal benefits and tech-only focus ...